Brown Advisory Inc. Sells 179 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Brown Advisory Inc. cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,734 shares of the medical research company’s stock after selling 179 shares during the period. Brown Advisory Inc.’s holdings in Charles River Laboratories International were worth $3,483,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in CRL. Teacher Retirement System of Texas boosted its holdings in Charles River Laboratories International by 2.5% in the third quarter. Teacher Retirement System of Texas now owns 3,964 shares of the medical research company’s stock valued at $777,000 after acquiring an additional 95 shares during the last quarter. Wealthfront Advisers LLC boosted its holdings in Charles River Laboratories International by 17.5% in the third quarter. Wealthfront Advisers LLC now owns 1,379 shares of the medical research company’s stock valued at $270,000 after acquiring an additional 205 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in Charles River Laboratories International by 6.6% in the third quarter. Daiwa Securities Group Inc. now owns 4,284 shares of the medical research company’s stock valued at $840,000 after acquiring an additional 266 shares during the last quarter. M&T Bank Corp boosted its holdings in Charles River Laboratories International by 3.3% in the third quarter. M&T Bank Corp now owns 2,076 shares of the medical research company’s stock valued at $407,000 after acquiring an additional 66 shares during the last quarter. Finally, California Public Employees Retirement System boosted its holdings in Charles River Laboratories International by 3.0% in the third quarter. California Public Employees Retirement System now owns 98,973 shares of the medical research company’s stock valued at $19,397,000 after acquiring an additional 2,841 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the sale, the executive vice president now directly owns 23,276 shares in the company, valued at approximately $5,282,953.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Victoria L. Creamer sold 5,000 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CRL shares. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. TD Cowen cut their price target on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a report on Monday, May 13th. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Evercore ISI increased their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Finally, Guggenheim cut Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $255.27.

Charles River Laboratories International Price Performance

Shares of CRL opened at $219.00 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. The business’s fifty day moving average is $243.85 and its 200 day moving average is $228.87. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The stock has a market cap of $11.28 billion, a P/E ratio of 25.76, a P/E/G ratio of 2.10 and a beta of 1.44.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.05 by $0.22. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).